117 related articles for article (PubMed ID: 38421673)
1. Mortality Risks Over 20 Years in Men With Stage I to III Hormone Receptor-Positive Breast Cancer.
Leone J; Hassett MJ; Freedman RA; Tolaney SM; Graham N; Tayob N; Vallejo CT; Winer EP; Lin NU; Leone JP
JAMA Oncol; 2024 Apr; 10(4):508-515. PubMed ID: 38421673
[TBL] [Abstract][Full Text] [Related]
2. Twenty-year risks of breast cancer-specific mortality for stage III breast cancer in the surveillance, epidemiology, and end results registry.
Leone JP; Leone BA; Tayob N; Hassett MJ; Leone J; Freedman RA; Tolaney SM; Winer EP; Vallejo CT; Lin NU
Breast Cancer Res Treat; 2021 Jun; 187(3):843-852. PubMed ID: 33590387
[TBL] [Abstract][Full Text] [Related]
3. Factors associated with late risks of breast cancer-specific mortality in the SEER registry.
Leone JP; Vallejo CT; Hassett MJ; Leone J; Graham N; Tayob N; Freedman RA; Tolaney SM; Leone BA; Winer EP; Lin NU
Breast Cancer Res Treat; 2021 Aug; 189(1):203-212. PubMed ID: 33893907
[TBL] [Abstract][Full Text] [Related]
4. Estimating long-term mortality in women with hormone receptor-positive breast cancer: The 'ESTIMATE' tool.
Leone JP; Graham N; Tolaney SM; Leone BA; Freedman RA; Hassett MJ; Leone J; Vallejo CT; Winer EP; Lin NU; Tayob N
Eur J Cancer; 2022 Sep; 173():20-29. PubMed ID: 35841843
[TBL] [Abstract][Full Text] [Related]
5. Different patterns in the prognostic value of age for breast cancer-specific mortality depending on hormone receptor status: a SEER population-based analysis.
Liu YR; Jiang YZ; Yu KD; Shao ZM
Ann Surg Oncol; 2015 Apr; 22(4):1102-10. PubMed ID: 25249260
[TBL] [Abstract][Full Text] [Related]
6. Hazard of breast cancer-specific mortality among women with estrogen receptor-positive breast cancer after five years from diagnosis: implication for extended endocrine therapy.
Yu KD; Wu J; Shen ZZ; Shao ZM
J Clin Endocrinol Metab; 2012 Dec; 97(12):E2201-9. PubMed ID: 22993034
[TBL] [Abstract][Full Text] [Related]
7. Effect of tumor size on breast cancer-specific survival stratified by joint hormone receptor status in a SEER population-based study.
Zheng YZ; Wang L; Hu X; Shao ZM
Oncotarget; 2015 Sep; 6(26):22985-95. PubMed ID: 26036636
[TBL] [Abstract][Full Text] [Related]
8. Radiotherapy and Male Breast Cancer: A Population-based Registry Analysis.
Madden NA; Macdonald OK; Call JA; Schomas DA; Lee CM; Patel S
Am J Clin Oncol; 2016 Oct; 39(5):458-62. PubMed ID: 24781343
[TBL] [Abstract][Full Text] [Related]
9. Outcomes of patients with inflammatory breast cancer by hormone receptor- and HER2-defined molecular subtypes: A population-based study from the SEER program.
Li J; Xia Y; Wu Q; Zhu S; Chen C; Yang W; Wei W; Sun S
Oncotarget; 2017 Jul; 8(30):49370-49379. PubMed ID: 28472761
[TBL] [Abstract][Full Text] [Related]
10. Estimating mortality in women with triple-negative breast cancer: The 'ESTIMATE triple-negative' tool.
Leone JP; Graham N; Leone J; Tolaney SM; Leone BA; Freedman RA; Hassett MJ; Vallejo CT; Winer EP; Lin NU; Tayob N
Eur J Cancer; 2023 Aug; 189():112930. PubMed ID: 37356327
[TBL] [Abstract][Full Text] [Related]
11. Quantifying the relationship between age at diagnosis and breast cancer-specific mortality.
Johnson HM; Irish W; Muzaffar M; Vohra NA; Wong JH
Breast Cancer Res Treat; 2019 Oct; 177(3):713-722. PubMed ID: 31297648
[TBL] [Abstract][Full Text] [Related]
12. Breast cancer-specific mortality in early breast cancer as defined by high-risk clinical and pathologic characteristics.
Nelson DR; Brown J; Morikawa A; Method M
PLoS One; 2022; 17(2):e0264637. PubMed ID: 35213669
[TBL] [Abstract][Full Text] [Related]
13. Neighborhood Disadvantage, African Genetic Ancestry, Cancer Subtype, and Mortality Among Breast Cancer Survivors.
Iyer HS; Zeinomar N; Omilian AR; Perlstein M; Davis MB; Omene CO; Pawlish K; Demissie K; Hong CC; Yao S; Ambrosone CB; Bandera EV; Qin B
JAMA Netw Open; 2023 Aug; 6(8):e2331295. PubMed ID: 37647068
[TBL] [Abstract][Full Text] [Related]
14. Breast cancer receptor status and stage at diagnosis in over 1,200 consecutive public hospital patients in Soweto, South Africa: a case series.
McCormack VA; Joffe M; van den Berg E; Broeze N; Silva Idos S; Romieu I; Jacobson JS; Neugut AI; Schüz J; Cubasch H
Breast Cancer Res; 2013; 15(5):R84. PubMed ID: 24041225
[TBL] [Abstract][Full Text] [Related]
15. Overall Survival of Men and Women With Breast Cancer According to Tumor Subtype: A Population-based Study.
Leone J; Zwenger AO; Leone BA; Vallejo CT; Leone JP
Am J Clin Oncol; 2019 Feb; 42(2):215-220. PubMed ID: 30499840
[TBL] [Abstract][Full Text] [Related]
16. Impact of Primary Tumor Surgery in Stage IV Male Breast Cancer.
Muzaffar M; Kachare S; Vohra N
Clin Breast Cancer; 2017 Jun; 17(3):e143-e149. PubMed ID: 27998656
[TBL] [Abstract][Full Text] [Related]
17. Identify high risk estrogen receptor-positive breast cancer patients for extended endocrine therapy.
Li J; Jiang Y; Liu Y; Shao Z
Breast; 2017 Feb; 31():173-180. PubMed ID: 27866092
[TBL] [Abstract][Full Text] [Related]
18. Breast Cancer-Specific Mortality in Small-Sized Tumor with Stage IV Breast Cancer: A Population-Based Study.
Zheng YZ; Wang XM; Fan L; Shao ZM
Oncologist; 2021 Feb; 26(2):e241-e250. PubMed ID: 33075188
[TBL] [Abstract][Full Text] [Related]
19. Poorer breast cancer survival outcomes in males than females might be attributable to tumor subtype.
Wu Q; Li J; Zhu S; Wu J; Li X; Liu Q; Wei W; Sun S
Oncotarget; 2016 Dec; 7(52):87532-87542. PubMed ID: 27655704
[TBL] [Abstract][Full Text] [Related]
20. Variation in Breast Cancer Subtype Incidence and Distribution by Race/Ethnicity in the United States From 2010 to 2015.
Kong X; Liu Z; Cheng R; Sun L; Huang S; Fang Y; Wang J
JAMA Netw Open; 2020 Oct; 3(10):e2020303. PubMed ID: 33074325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
